JP2023547978A5 - - Google Patents

Info

Publication number
JP2023547978A5
JP2023547978A5 JP2023510318A JP2023510318A JP2023547978A5 JP 2023547978 A5 JP2023547978 A5 JP 2023547978A5 JP 2023510318 A JP2023510318 A JP 2023510318A JP 2023510318 A JP2023510318 A JP 2023510318A JP 2023547978 A5 JP2023547978 A5 JP 2023547978A5
Authority
JP
Japan
Prior art keywords
isolated polypeptide
polypeptide according
antigen
cleavable linker
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023510318A
Other languages
English (en)
Japanese (ja)
Other versions
JP7681681B2 (ja
JP2023547978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045395 external-priority patent/WO2022035866A1/en
Publication of JP2023547978A publication Critical patent/JP2023547978A/ja
Publication of JP2023547978A5 publication Critical patent/JP2023547978A5/ja
Priority to JP2025078945A priority Critical patent/JP2025131591A/ja
Application granted granted Critical
Publication of JP7681681B2 publication Critical patent/JP7681681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023510318A 2020-08-11 2021-08-10 切断可能リンカー組成物および方法 Active JP7681681B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078945A JP2025131591A (ja) 2020-08-11 2025-05-09 切断可能リンカー組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064268P 2020-08-11 2020-08-11
US63/064,268 2020-08-11
PCT/US2021/045395 WO2022035866A1 (en) 2020-08-11 2021-08-10 Cleavable linker compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078945A Division JP2025131591A (ja) 2020-08-11 2025-05-09 切断可能リンカー組成物および方法

Publications (3)

Publication Number Publication Date
JP2023547978A JP2023547978A (ja) 2023-11-15
JP2023547978A5 true JP2023547978A5 (cg-RX-API-DMAC7.html) 2024-08-07
JP7681681B2 JP7681681B2 (ja) 2025-05-22

Family

ID=80223911

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023510318A Active JP7681681B2 (ja) 2020-08-11 2021-08-10 切断可能リンカー組成物および方法
JP2025078945A Pending JP2025131591A (ja) 2020-08-11 2025-05-09 切断可能リンカー組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078945A Pending JP2025131591A (ja) 2020-08-11 2025-05-09 切断可能リンカー組成物および方法

Country Status (10)

Country Link
US (3) US11512113B2 (cg-RX-API-DMAC7.html)
EP (2) EP4196488B1 (cg-RX-API-DMAC7.html)
JP (2) JP7681681B2 (cg-RX-API-DMAC7.html)
KR (2) KR102944047B1 (cg-RX-API-DMAC7.html)
CN (1) CN116348597A (cg-RX-API-DMAC7.html)
AU (2) AU2021326469C1 (cg-RX-API-DMAC7.html)
CA (1) CA3187754A1 (cg-RX-API-DMAC7.html)
ES (1) ES3040950T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023001788A (cg-RX-API-DMAC7.html)
WO (1) WO2022035866A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111247171A (zh) * 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US12534734B2 (en) * 2018-05-15 2026-01-27 Drive Therapeutics Llc Stem-loop compositions and methods for inhibiting interleukin-8
AU2021326469C1 (en) * 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
KR20250024874A (ko) * 2022-04-04 2025-02-19 재눅스 테라퓨틱스 인크. Psma 및 이펙터 세포 항원을 표적으로 하는 종양 활성화 항체와 관련된 조성물 및 방법
WO2024100451A2 (en) * 2022-11-11 2024-05-16 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
CN122349537A (zh) 2023-12-01 2026-07-07 阿布林克斯有限公司 识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体
WO2025201560A1 (en) * 2024-03-29 2025-10-02 Vibrant Pharma Limited Multispecific antigen-binding proteins and uses thereof
GB2641580A (en) * 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
US20260226165A1 (en) * 2024-12-17 2026-08-06 Merck Sharp & Dohme Llc Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US20010031264A1 (en) 1996-01-25 2001-10-18 Andrew Segal Vaccine compositions and methods of modulating immune responses
JP2009540015A (ja) 2006-06-14 2009-11-19 イムクローン・リミテッド・ライアビリティ・カンパニー 抗egfr抗体の凍結乾燥製剤
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016077505A2 (en) * 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
AU2017364818C1 (en) * 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
JP2022512124A (ja) * 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
US20230220105A1 (en) 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
WO2020264200A1 (en) 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
AU2021326469C1 (en) * 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods

Similar Documents

Publication Publication Date Title
JP2022512124A5 (cg-RX-API-DMAC7.html)
JP2023552812A5 (cg-RX-API-DMAC7.html)
JP2023526428A5 (cg-RX-API-DMAC7.html)
US20220017640A1 (en) Activatable bispecific antibodies
JP2019513014A5 (cg-RX-API-DMAC7.html)
JP2022046569A5 (cg-RX-API-DMAC7.html)
AU2026202575A1 (en) Matrix Metalloprotease-Cleavable And Serine Or Cysteine Protease-Cleavable Substrates And Methods Of Use Thereof
JP2021004250A (ja) 改変した抗体組成物、それを作製および使用する方法
CN102665768B (zh) 肽清除剂
CN116655799A (zh) 包括可切割接头的il-2细胞因子前药
JP2018504925A5 (cg-RX-API-DMAC7.html)
JP2024518539A5 (cg-RX-API-DMAC7.html)
JP2023552462A5 (cg-RX-API-DMAC7.html)
JP2016511279A (ja) 免疫リガンド/ペイロード複合体の生産方法
CN111278467A (zh) 抗cd71可活化抗体药物缀合物和其使用方法
US20260055205A1 (en) Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
US12590159B2 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
JP2024527020A5 (cg-RX-API-DMAC7.html)
CN119462956A (zh) 接头多肽
TW201437229A (zh) 抗活化蛋白c之人化單株抗體及其用途
JP2024531338A5 (cg-RX-API-DMAC7.html)
WO2006033413A1 (ja) ペプチドの定量方法
JPWO2023068377A5 (cg-RX-API-DMAC7.html)
WO2021256524A1 (ja) 免疫原性低減型低分子抗体とその製造法
US20190270828A1 (en) Tandem antibodies